Global equity markets witnessed extraordinary momentum in the pharmaceutical space as shares of American biotechnology firm Moderna experienced a historic rally during Thursday's trading session. Widely recognized for developing one of the primary COVID-19 vaccines during the global pandemic, the company saw an aggressive buying surge following breakthrough news regarding its pipeline cancer treatment. The announcement of successful late-stage clinical trial outcomes for a joint cancer vaccine triggered an immediate rush among investors, driving the stock up by more than 177 percent in a single day.
Breakthrough Trial Results Spark Historic Single-Day Rally
Trading in Moderna on the US stock exchanges started with intense bullish sentiment. The stock had closed at $62.51 in the preceding trading session. As trading opened on Thursday, aggressive purchasing pushed the share price past the $116 threshold within a brief period. The momentum continued unabated throughout the session, driving the stock up by over 177 percent to a new all-time high of $176.66. By the close of the market, Moderna shares settled at $174.38, reflecting an impressive single-day gain of 173 percent. Translated into Indian currency, the stock reached approximately ₹16,740 per share. Based on these movements, an investment of ₹1 lakh made on Thursday grew to approximately ₹2.76 lakh (or ₹2,77,000) by the end of the day.
Strategic Collaboration with Merck Achieves Melanoma Milestones
The catalyst behind this remarkable market performance stems from Moderna's partnership with pharmaceutical giant Merck. Both organizations confirmed that their investigational mRNA cancer treatment vaccine successfully achieved its primary targets in late-stage clinical testing for melanoma. Melanoma represents a highly aggressive form of skin cancer, making this trial milestone a major clinical breakthrough. The positive trial data reassurances resonated strongly across global capital markets, creating high demand for Moderna shares and solidifying its status as a high-performing multibagger stock.
Consistent Multibagger Returns Across Extended Timeframes
Beyond its single-day surge, Moderna's stock performance has demonstrated extraordinary growth over longer investment horizons. Over the past year, the company's shares have multiplied investor capital sixfold, delivering a massive 548.49 percent return over the 12-month period. Mathematically, a capital allocation of ₹1 lakh in Moderna shares one year ago would have expanded to roughly ₹6 lakh today. Additionally, the stock has appreciated by 250 percent over the past six months and recorded a gain of nearly 194 percent over the past month alone, highlighting sustained investor confidence in its commercial and therapeutic roadmap.
